Key result
Third-generation biodegradable polymer Biomatrix stents were associated with a higher mean utility value and a gain of 0.035 QALYs compared to Xience stents at 1 year.
Why the study?
Quality of life data for coronary revascularization options are scarce, and the utility scores and quality-adjusted life years of second- versus third-generation drug-eluting stents had not been compared.
Does 3rd generation BP-Biomatrix DES improve utility scores and QALYs compared to 2nd generation DP-Xience DES in patients undergoing primary PCI for STEMI?
Cohort (n=334)
No
Does 3rd generation BP-Biomatrix DES improve utility scores and QALYs compared to 2nd generation DP-Xience DES in patients undergoing primary PCI for STEMI?
Biodegradable polymer Biomatrix stents are associated with better health-related quality of life and QALYs at 1 year compared to durable polymer Xience stents in patients undergoing primary PCI.
Answers are grounded in this paper and cite their sources.
May suggest QALY advantage for Biomatrix stents; leaves open confirmation in randomized trials before practice change.
BACKGROUND: Primary percutaneous coronary intervention (PPCI) is the recommended treatment in ST elevated myocardial infarction (STEMI). The determination of Quality of life (QoL) for various options of coronary revascularization is important for establishment of a comprehensive care plan. Studies of QoL in interventional cardiology are scarce. Our study has compared utility scores and quality adjusted life year (QALY) of 2nd and 3rd generation drug eluting stents (DES). METHODS: An observational cohort study was conducted to evaluate QoL and QALY using EQ-5D-5L questionnaire. Patients undergoing PPCI between July-Dec 2019 were evaluated after completion of one year of procedure. RESULTS: Total 334 patients were evaluated, study population consisted of a greater number of males (87.13%) than females. Mean utility value was more in 3rd G Biomatrix stents; 0.829 ± 0.11 than 2nd G Xience stents; 0.794 ± 0.11 (p < 0.05). Visual analogue scale (VAS) value was also high in 3rd G DES (81.84 ± 8.29) as compared to 2nd G DES (77.81 ± 9.01); p< 0.05. A significant association was found between utility scores/VAS and age, DM, HTN, Current smoking, family history and CAD diagnosis. There was a gain of 0.035 QALY with the use of Biomatrix DES. CONCLUSION: Health related quality of life (HRQOL) is a leading support in the decision making of therapeutic interventions. Our study has found that Biodegradable polymer (BP) Biomatrix DES are superior to the Durable polymer (DP) Xience DES having better QoL and QALY.
No takes yet. Share an insight, caveat, or question.
Bibi et al. (2021) conducted a cohort in Coronary Artery Disease (STEMI) (n=334). 3rd generation biodegradable polymer (BP) Biomatrix stents vs. 2nd generation durable polymer (DP) Xience stents was evaluated on Mean utility value (EQ-5D-5L) (p=<0.05). Third-generation biodegradable polymer Biomatrix stents were associated with a higher mean utility value and a gain of 0.035 QALYs compared to Xience stents at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: